Surfactant Replacement Therapy And The Affects On Rds And Other Pulmonary Disorders

Best Essays
Surfactant Replacement Therapy and the Affects on RDS and Other Pulmonary Disorders Jacquelyn M. Wood Grossmont Community College 2015 INTRODUCTION As a newborn makes their entrance to this world from intrauterine life all should go smoothly. The newborn is delivered and is stimulated to breathe and then is followed by inspirations, followed by a cry showing a successful arrival to this world, but not all deliveries go as planned. There are diseases of the respiratory system. The most common disease is Respiratory Distress Syndrome (RDS). The Primary cause of RDS is the underdevelopment of the premature lungs states Perretta, 2015. RDS is caused by a deficiency and immaturity of alveolar surfactant with the anatomical immaturity of the premature infants lungs. The incidence of RDS increases with decreasing gestational age says J. Haitsma, 2010. The biggest factor is surfactant deficiency caused by decreased surface area in the lungs for proper gas exchange and thick alveolar-capillary membranes. “Surfactant replacement therapy for preterm infants with RDS has shown to be a major breakthrough in neonatal medicine,” says J. Wirbelauer and Speer, 2009. It has become routine for the prevention and treatment for infants suffering from respiratory distress syndrome. Surfactant replacement therapy is a life-saving treatment for all neonates showing signs of RDS characterized by surfactant deficiency. By replenishing the lungs with an exogenous surfactant shows
Get Access